Lakewood-Amedex Biotherapeutics Goes Public on Nasdaq
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Should l Buy LABT?
Source: NASDAQ.COM
- Trading Overview: Lakewood-Amedex Biotherapeutics Inc. (LABT) began trading on the Nasdaq Capital Market via a direct listing, opening at $8.00 and closing at $8.65, reflecting an 8.12% increase, indicating strong initial market interest.
- Clinical Trial Plans: The company plans to initiate a Phase 2a clinical trial for its lead candidate Nu-3 targeting infected diabetic foot ulcers, addressing the significant challenge posed by antibiotic-resistant pathogens for nearly 40 million diabetic patients in the U.S.
- Market Potential: Approximately one-third of diabetes patients will develop diabetic foot ulcers in their lifetime, with around 50% facing infections, highlighting the critical need for effective treatments amidst rising antibiotic resistance, positioning LABT's research as highly relevant.
- Investor Awareness: Management noted that visibility on Nasdaq will accelerate clinical development and broaden investor awareness of its pipeline, which is expected to further drive the company's growth in the biotechnology sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LABT
Wall Street analysts forecast LABT stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 8.650
Low
Averages
High
Current: 8.650
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lakewood-Amedex Biotherapeutics Begins Trading on Nasdaq Under LABT
- Listing Achievement: Lakewood-Amedex Biotherapeutics commenced trading on the Nasdaq Capital Market today under the ticker symbol 'LABT', marking a significant milestone that enables accelerated development of its Bisphosphocin® antimicrobial drugs, particularly the lead product Nu-3.
- Clinical Trial Plans: The company plans to initiate a Phase 2a clinical trial for infected diabetic foot ulcers (iDFU) shortly, addressing a significant market need as nearly 40 million people in the U.S. have diabetes, with about one-third developing DFUs and 50% of those becoming infected.
- Antibiotic Resistance Challenge: The development of Nu-3 is critical in light of rising antibiotic-resistant bacterial strains, as it aims to rapidly eliminate a broad spectrum of bacteria, including resistant pathogens, thereby meeting the urgent demand for new therapies in the market.
- Initial Clinical Data: Preliminary exploratory clinical trials indicated no safety signals with subclinical doses of Nu-3 and showed a trend towards positive antimicrobial response and improved wound healing, laying the groundwork for subsequent Phase 2a safety and dose-response studies.
See More
Lakewood-Amedex Biotherapeutics Listing Accelerates Development of Nu-3
- Listing Accelerates R&D: Lakewood-Amedex Biotherapeutics Chairman Doug Manion stated that the listing will expedite the development of the bisphosphocin class of compounds, particularly the lead product Nu-3 aimed at treating infected diabetic foot ulcers.
- Clinical Trial Plans: CEO Kelvin Cooper announced plans to initiate a Phase 2a clinical trial for Nu-3, addressing the significant market need as one-third of the 40 million diabetes patients in the U.S. develop diabetic foot ulcers during their lifetime.
- Stock Surge: Shares of Lakewood-Amedex soared over 8% on their first day of trading on Nasdaq, followed by a remarkable 70% increase in pre-market trading on Friday, bringing the market capitalization to $122 million, indicating strong investor confidence in the company's future.
- Positive Early Trial Results: The company reported that early exploratory trials of Nu-3 at subclinical doses showed no safety concerns and indicated a trend toward antimicrobial activity and improved wound healing, with plans for a subsequent Phase 2b trial to assess different dosing effects.
See More
Lakewood-Amedex Biotherapeutics Goes Public on Nasdaq
- Trading Overview: Lakewood-Amedex Biotherapeutics Inc. (LABT) began trading on the Nasdaq Capital Market via a direct listing, opening at $8.00 and closing at $8.65, reflecting an 8.12% increase, indicating strong initial market interest.
- Clinical Trial Plans: The company plans to initiate a Phase 2a clinical trial for its lead candidate Nu-3 targeting infected diabetic foot ulcers, addressing the significant challenge posed by antibiotic-resistant pathogens for nearly 40 million diabetic patients in the U.S.
- Market Potential: Approximately one-third of diabetes patients will develop diabetic foot ulcers in their lifetime, with around 50% facing infections, highlighting the critical need for effective treatments amidst rising antibiotic resistance, positioning LABT's research as highly relevant.
- Investor Awareness: Management noted that visibility on Nasdaq will accelerate clinical development and broaden investor awareness of its pipeline, which is expected to further drive the company's growth in the biotechnology sector.
See More
Lakewood-Amedex Biotherapeutics Begins Trading on Nasdaq
- Listing Achievement: Lakewood-Amedex Biotherapeutics Inc. commenced trading on the Nasdaq Capital Market today under the ticker symbol "LABT", marking a significant milestone that opens new avenues for the development of its Bisphosphocin® class of antimicrobials.
- Clinical Trial Plans: The company plans to initiate a Phase 2a clinical trial for infected diabetic foot ulcers (iDFU) shortly, addressing the needs of nearly 40 million diabetics in the U.S., with one-third likely to develop DFUs and about 50% experiencing infections.
- Antibiotic Resistance Challenge: The development of Lakewood-Amedex's Bisphosphocin® class is crucial in the face of rising antibiotic-resistant strains, aiming to meet the significant unmet medical needs particularly among diabetic patients.
- Nu-3 Product Outlook: Nu-3, the company's lead product for mildly infected diabetic foot ulcers, has shown promising antimicrobial responses and improved wound healing in initial trials, with plans for larger Phase 2b comparative studies to validate its efficacy.
See More
Lakewood-Amedex Biotherapeutics Begins Trading on Nasdaq Under LABT
- Listing Achievement: Lakewood-Amedex Biotherapeutics commenced trading on the Nasdaq Capital Market today under the ticker symbol 'LABT', marking a significant milestone that enables accelerated development of its Bisphosphocin® antimicrobial drugs, particularly the lead product Nu-3.
- Clinical Trial Plans: The company plans to initiate a Phase 2a clinical trial for infected diabetic foot ulcers (iDFU) shortly, addressing a significant market need as nearly 40 million people in the U.S. have diabetes, with about one-third developing DFUs and 50% of those becoming infected.
- Antibiotic Resistance Challenge: The development of Nu-3 is critical in light of rising antibiotic-resistant bacterial strains, as it aims to rapidly eliminate a broad spectrum of bacteria, including resistant pathogens, thereby meeting the urgent demand for new therapies in the market.
- Initial Clinical Data: Preliminary exploratory clinical trials indicated no safety signals with subclinical doses of Nu-3 and showed a trend towards positive antimicrobial response and improved wound healing, laying the groundwork for subsequent Phase 2a safety and dose-response studies.
See More
Lakewood-Amedex Biotherapeutics Listing Accelerates Development of Nu-3
- Listing Accelerates R&D: Lakewood-Amedex Biotherapeutics Chairman Doug Manion stated that the listing will expedite the development of the bisphosphocin class of compounds, particularly the lead product Nu-3 aimed at treating infected diabetic foot ulcers.
- Clinical Trial Plans: CEO Kelvin Cooper announced plans to initiate a Phase 2a clinical trial for Nu-3, addressing the significant market need as one-third of the 40 million diabetes patients in the U.S. develop diabetic foot ulcers during their lifetime.
- Stock Surge: Shares of Lakewood-Amedex soared over 8% on their first day of trading on Nasdaq, followed by a remarkable 70% increase in pre-market trading on Friday, bringing the market capitalization to $122 million, indicating strong investor confidence in the company's future.
- Positive Early Trial Results: The company reported that early exploratory trials of Nu-3 at subclinical doses showed no safety concerns and indicated a trend toward antimicrobial activity and improved wound healing, with plans for a subsequent Phase 2b trial to assess different dosing effects.
See More
Lakewood-Amedex Biotherapeutics Goes Public on Nasdaq
- Trading Overview: Lakewood-Amedex Biotherapeutics Inc. (LABT) began trading on the Nasdaq Capital Market via a direct listing, opening at $8.00 and closing at $8.65, reflecting an 8.12% increase, indicating strong initial market interest.
- Clinical Trial Plans: The company plans to initiate a Phase 2a clinical trial for its lead candidate Nu-3 targeting infected diabetic foot ulcers, addressing the significant challenge posed by antibiotic-resistant pathogens for nearly 40 million diabetic patients in the U.S.
- Market Potential: Approximately one-third of diabetes patients will develop diabetic foot ulcers in their lifetime, with around 50% facing infections, highlighting the critical need for effective treatments amidst rising antibiotic resistance, positioning LABT's research as highly relevant.
- Investor Awareness: Management noted that visibility on Nasdaq will accelerate clinical development and broaden investor awareness of its pipeline, which is expected to further drive the company's growth in the biotechnology sector.
See More
Lakewood-Amedex Biotherapeutics Begins Trading on Nasdaq
- Listing Achievement: Lakewood-Amedex Biotherapeutics Inc. commenced trading on the Nasdaq Capital Market today under the ticker symbol "LABT", marking a significant milestone that opens new avenues for the development of its Bisphosphocin® class of antimicrobials.
- Clinical Trial Plans: The company plans to initiate a Phase 2a clinical trial for infected diabetic foot ulcers (iDFU) shortly, addressing the needs of nearly 40 million diabetics in the U.S., with one-third likely to develop DFUs and about 50% experiencing infections.
- Antibiotic Resistance Challenge: The development of Lakewood-Amedex's Bisphosphocin® class is crucial in the face of rising antibiotic-resistant strains, aiming to meet the significant unmet medical needs particularly among diabetic patients.
- Nu-3 Product Outlook: Nu-3, the company's lead product for mildly infected diabetic foot ulcers, has shown promising antimicrobial responses and improved wound healing in initial trials, with plans for larger Phase 2b comparative studies to validate its efficacy.
See More
